Get a free sample of U.S. Heparin Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of U.S. Heparin Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
U.S. Heparin Market Size
U.S. Heparin Market size exceeded USD 623 million in 2019 and is poised to grow at over 7.2% CAGR between 2020 and 2026. Increasing patient pool suffering from chronic illness and rising demand for anticoagulant products will drive the market growth.
Heparin is primarily used in blood transfusion, deep vein thrombosis and kidney dialysis, among others. For instance, according to the National Kidney Foundation report, more than 37 million (15%) individual of U.S. adults are affected by chronic kidney disease (CKD). The report also stated that CKD causes more deaths than breast cancer or prostate cancer. It is one of the under-recognized public health crises. This indicates that there will huge number of patient pool suffering from such disease. Such high prevalence of the disease will increase the heparin market demand in the U.S.
Heparin is an essential anticoagulant drug that are used in critical life-saving surgical procedures. Thus, it can be expected that the COVID-19 outbreak will not directly impact on the manufacturing of products. However, there can be logistical disruptions especially due to the high reliance on Chinese manufacturing. This could disrupt the supply system of heparin and may cause temporary shortages. This can potentially increase the price of heparin API.
What factors will contribute to the augmentation of the U.S. heparin market share?
Driven by a rising patient pool suffering from chronic illness coupled with increasing demand for anticoagulant products, the U.S. industry size of heparin surpassed USD 623 million in 2019 and is set to expand at more than 7.2% CAGR through 2026.
Why will the increasing prevalence of venous thromboembolism prove lucrative for the U.S. heparin industry revenue growth?
The venous thromboembolism segment accounted for USD 328 million in 2019 and is likely to grow at a 6.8% rate through 2026 favoured by the rising number of patients requiring heparin for treatment of venous thromboembolism.
How will low molecular weight heparin influence the industry size growth?
The low molecular weight heparin segment revenue in the U.S. was over USD 535.4 million in 2019 and is poised to grow substantially owing to its distinct biochemical and pharmacological properties.
How will the growing inclination towards hospital pharmacy impact the heparin market size in the U.S.?
The hospital pharmacy segment held a market share of 54.3% in 2019, and the rising preference of patients towards hospitals due to ease of availability of medicines will boost the market growth.